Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension
In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH.
This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.
Amid last week's news that CMS had miscalculated the number of enrollees under the Affordable Care Act was a quieter announcement that the agency had appointed a chief data office to improve transparency, among other tasks.
Genentech's decision to use a handful of specialty drug distributors instead of wholesalers for the distribution of the most commonly used anticancer medications has raised concerns of availability and cost.
A commentary in this month’s issue of The American Journal of Managed Care explores whether allowing generic versions of medications to look like branded equivalents would be better for consumers and improve adherence.
The disclosure that a calculation error caused the Obama administration to add an extra 400,000 people to ACA enrollment figures for months puts a dent in the 2015 open enrollment, in part because it fits a narrative of a lack of transparency for reporters who cover the administration.
Vermont Senator Bernie Sanders has introduced a bill that would require generic drugmakers to pay rebates to the federal Medicare and Medicaid programs when prices of their medications outpace inflation.
A new study shows only a small share of patients with private insurance who were newly diagnosed with diabetes in 2011-2012 enrolled in self-management training, raising questions about how well managed care could address both long-term health and cost control for this important group. These patients are a target for special attention under the ACA.